Boston Scientific Corp. has exercised its option to acquire the remaining shares of University of Iowa startup Farapulse Inc., which has developed a method for precisely and safely treating abnormal heart rhythms.
A growing number of Iowa-based companies trace their roots to federally funded University of Iowa research that helps them create jobs, generate wages, boost the local and state economy, and produce new knowledge, inventions, and services, according to a recent report by The Science Coalition (TSC).
University of Iowa spinoff Cardio Diagnostics Inc., a company that assesses genetic and epigenetic DNA markers to monitor a patient's risk for heart disease, was recently selected a “one to watch” in this year’s inaugural Spinoff Prize, organized by Nature Research and Merck KGaA.
A University of Iowa (UI) spin-out company developing a drug-delivering mechanism to prevent the onset of post-traumatic osteoarthritis recently earned second place—and $25,000—in the 2019 John Pappajohn Iowa Entrepreneurial Venture Competition.
A system designed by a University of Iowa ophthalmologist that uses artificial intelligence (AI) to detect diabetic retinopathy without a person interpreting the results earned Food and Drug Administration (FDA) authorization in April, following a clinical trial in primary care offices. Results of that study were published Aug. 28 online in Nature Digital Medicine, offering the first look at data that led to FDA clearance for IDx-DR, the first medical device that uses AI for the autonomous detection of diabetic retinopathy.
University of Iowa spinout company Voxello, which develops technologies that allow hospitalized patients to overcome communication barriers, recently received three grants to help advance its research and development.
Having clear and up-to-date protocols and policies around intellectual property (IP) is critically important for moving discovery at the University of Iowa forward. It ensures that inventions by faculty and staff are clearly identified, adequately protected, and leveraged in a way that benefits the inventor, the university, and the public—should the IP eventually translate into a commercial product, service, or company.